2025
Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families
Benedict C, Bloomer K, Billman E, Smith M, Boynton H, Schapira L, Smith S. Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families. Psycho-Oncology 2025, 34: e70120. PMID: 40097346, DOI: 10.1002/pon.70120.Peer-Reviewed Original ResearchConceptsAYA survivors of childhood cancerSurvivors of childhood cancerChildhood cancerAYA survivorsFinancial toxicityAdolescent/young adultPerspectives of staff membersNon-English language preferenceStaff membersCancer support organizationsThematic analysis approachCommunity-based organizationsRural regionsParental employmentIndirect medical costsNeeds assessment studySemi-structured interviewsMedical visitsVulnerable populationsLanguage preferenceInsurance coverageMedical costsQualitative dataRural areasMinoritized families
2023
Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States
Ito S, Chetlapalli K, Potnis K, Richmond R, Wang D, Lee A, Goshua G. Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States. Blood 2023, 142: 5042. DOI: 10.1182/blood-2023-188063.Peer-Reviewed Original ResearchTreatment-experienced patientsParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitIncremental cost-effectiveness ratioNursing timeExtravascular hemolysisNocturnal hemoglobinuriaPhase III study resultsTreatment-experienced adult patientsTransfusion-associated adverse eventsCost-effective therapeutic optionAnti-C5 therapyComplement inhibition therapyComplement inhibitor therapyHealth resource utilizationCare of patientsIndirect medical costsComplement component 5Clinical trial dataLife-threatening hematological disorderCost-effectiveness ratioBreakthrough therapy designationProbabilistic sensitivity analysesFirst cost-effectiveness analysisCost-effectiveness analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply